Cardiology

Non-small cell lung cancer

Questions discussed in this category

How do you monitor for cardiac toxicity in patients taking osimertinib?

Do you routinely check EKGs or echocardiograms? Or do you decide only if the patient is at risk for QTc prolongation or other symptoms?

1 Answer available

Would you discontinue dabrafenib/trametinib in a patient with BRAF mutant metastatic lung cancer if you see mild cardiomyopathy which could be related to the drugs?

Patient does not want chemo but is tolerating these well otherwise.

1 Answer available

Papers discussed in this category

JACC CardioOncol, 2019 Dec 17

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Dec 23

Cardiac Safety of Osimertinib: A Review of Data.

JAMA network open, 2024 Dec 02

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.

JACC. CardioOncology, 2020 Mar 17

Cardiac Adverse Events in -Mutated Non-Small Cell Lung Cancer Treated With Osimertinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2024 Oct 10

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.

The New England journal of medicine, 2014-11-13

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Lancet Oncol., 2017 Sep 11

Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Related Topics in Cardiology